Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.
Illumina Company Profile
President & CEO: Francis deSouza
Ticker symbol: ILMN
Headquarters: San Diego, CA
Illumina employees: 5,500+ globally
Revenues: $2.4 Billion USD in 2016
Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel
ACMG: Rare Disease Patients in Poor Countries See Benefit from Clinical Whole-Genome Sequencing
Patients in Illumina's global iHope philanthropic clinical WGS program saw changes in their management regardless of whether they lived in wealthy or poor countries.
Illumina, Myriad Genetics Expand Partnership to Bring TSO 500 HRD Assay to US
The firms are creating a CDx alliance to help pursue HRD regulatory approvals for both the MyChoice HRD assay and a future clinical IVD test from Illumina.
Ravgen NIPT Patents Withstand Illumina Challenge
The US Patent Trial and Appeal Board delivered a pair of rulings stating that Illumina failed to show Ravgen's innovations should be considered unpatentable.
European Commission Outlines Intended Restorative Measures for Blocked Illumina-Grail Deal
In a Statement of Objections, the agency laid out the intended divestment and transitional measures for Illumina to unwind and dissolve the Grail acquisition.
Illumina, Al Jalila Children's Specialty Hospital Ink Rapid Whole-Genome Sequencing Deal
Illumina will provide sequencing reagents and analytical tools to the UAE hospital for a two-year study of the impact of clinical rWGS in neonatal and pediatric care units.